U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Explore the best investing ideas for 2025 at Investorideas.com. Get stock news, podcasts, videos, and insights on AI, crypto, ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed ...

Krystal Biotech, Inc. is a Pittsburgh ... fusion of the fingers and toes, GI tract issues, and ocular complications. It is caused by a mutation or multiple mutations of the COL7A1 gene, which ...

Based in the biotech hub of Massachusetts in the U.S., cancer vaccine ... which drives 25% of all solid tumors – ELI-007 targeting mBRAF in gastrointestinal (GI) tumors, and ELI-008 targeting mTP53 in ...

Oncolytics Biotech's main asset ... This was presented in a poster at ASCO GI 2025, showing that pelareorep treatment was feasible in the safety run-in. Nine patients were treated with the ...

It's often challenging to decide which stocks to invest in ... in line with the market in the past six months. A big biotech ...

Organovo’s stock skyrocketed 244% Tuesday on the news ... thought to hold potential across several gastrointestinal (GI) diseases. However, the drug class has faced several setbacks, namely ...

However, investors were disappointed and the stock fell following the announcement ... to GSK’s growing portfolio in gastrointestinal (GI) cancers, including ongoing trials with dostarlimab ...